# A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United States

> **NCT07260110** · — · RECRUITING · sponsor: **Sanofi** · enrollment: 550 (estimated)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** Teplizumab

## Key facts

- **NCT ID:** NCT07260110
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-31
- **Primary completion:** 2030-12-03
- **Final completion:** 2030-12-03
- **Target enrollment:** 550 (ESTIMATED)
- **Last updated:** 2025-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07260110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07260110, "A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United States". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07260110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*